A Case of Alopecia Areata in a Patient with Turner Syndrome

Serena Gianfaldoni1*, Georgi Tchernev2, Uwe Wollina3, Torello Lotti4

1University G. Marconi of Rome, Dermatology and Venereology, Rome 00192, Italy; 2Medical Institute of the Ministry of Interior, Dermatology, Venereology and Dermatologic Surgery, Onkoderma, Private Clinic for Dermatologic Surgery, Dermatology and Surgery, Sofia 1407, Bulgaria; 3Krankenhaus Dresden-Friedrichstadt, Department of Dermatology and Venereology, Dresden, Sachsen, Germany; 4Universitario di Ruolo, Dipartimento di Scienze Dermatologiche, Università degli Studi di Firenze, Facoltà di Medicina e Chirurgia, Dermatology, Via Vittoria Colonna 11, Rome 00186, Italy

Abstract

The Authors report a case of alopecia areata totalis in a woman with Turner syndrome.

Introduction

Alopecia areata (AA) is an inflammatory non-scarring form of hair loss, which may involve all the follicular units of the body. It is a common disease, with an incidence of 1-2% [1].

AA may affect people of both sex and all age, even if it is more commonly described in under 30-years old patients [2]. Often, it is associated with different inflammatory or autoimmune diseases, like atopic eczema, Hashimoto’s thyroiditis, Graves’ disease, Celiac disease, vitiligo, psoriasis and others [1].

AA is an autoimmune disease, characterised by a T-cell mediated immune response that targets hair follicles. The clinical manifestations are numerous, ranging from mild lesions, characterised by round or oval patches of hair loss, to the total hair loss, such as in the universal form [3].

Case report

A 28-year-old woman affected by AA, showed up to our Clinic presenting a widespread non-scarring alopecia, which was localised in the scalp and face area. The skin was white-pink in colour and normal-trophic. Black dots and exclamations points were not detected. Only a few vellus-like hairs were present in the midline of the scalp (Fig.1). The patient did not report any subjective symptoms and enjoyed apparent good health.

She reported the appearance of the disease about 26 months ago. Initially, the hair loss was limited to the left temporal side, and consisted in two round little (diameter less than 2 cm), well defined, areas. After few weeks, the hair loss rapidly spread, involving the entire scalp. By five months, the patient also observed the loss of her eyelashes and eyebrows.

The woman told us to be affected by Turner
syndrome, Hashimoto’s thyroiditis and celiac disease. Her medical treatment consisted of oral levothyroxine and oestrogen replacement. No other diseases had been reported. She had no familiarity for AA or other autoimmune diseases.

The patient reported previous treatment of alopecia with oral supplements and topical minoxidil 2% 1 ml twice a day for six months. Due to the lack of clinical improvement, she was treated with low dose of topical corticosteroids (hydrocortisone once a day) for three weeks and PUVA therapy, which has been performed twice a week for a total of 20 sessions, both without beneficial results.

Figure 1: Alopecia areata in a woman with Turner syndrome

During the clinical evaluation, the woman showed characteristic features of Turner syndrome, such as short stature (150 cm), short and squat neck, poor breast development and stubby little hands. She had ears and lower eyelids bigger than normal, enophthalmos, reduced upper lip and a small chin. On the other hand, no other skin lesions were observed. Nails were smaller than normal. A routine laboratory test, including thyroid function tests, were normal.

Figure 2: Eyelashes and eyebrows re-growth after cyclosporine A therapy

Due to the long duration of the hair disease, we applied intralesional triamcinolone acetonide once a week for two months. Surprisingly, even if localised, we observed a re-growth of the hair. Since hair growth responded to corticosteroids, we switched to oral methylprednisolone 32 mg/die for ten days, followed by 16 mg/die for ten days and, eventually 8 mg/die for another ten days. The clinical response was quite good: the patient showed new hair in the frontal area of the scalp.

After one month, we observed the diffuse hair re-growth on the scalp. New eyelashes and eyebrows were also observed (Fig.2).

We decided to reduce progressively the cyclosporine therapy and to stop it. Because of the appearance of new hair loss patches (Fig.3), the patient re-started the treatment with cyclosporine A at a dosage of 200 mg/die. The clinical response was rapid and excellent (Fig.4).

Figure 3: So we prescribed oral cyclosporine A 300 mg/die for two months, and intralesional triamcinolone acetonide once every two weeks. Due to the good clinical response to the therapy and the possible side effects of corticosteroids, after two months, we decided to prescribe the only cyclosporine A 200 mg/die

Figure 4: Our patient with complete hair re-growth
During the treatment we constantly evaluated the patient’s clinical conditions, monitoring her blood pressure and routine blood test. No side effects or complications were observed.

Discussion

Turner syndrome (or Ullrich-Turner syndrome) is one of the most frequent chromosomal abnormalities, which results from a sex-chromosomal anomaly characterised by a presence of one normal X chromosome and a missing or structurally abnormal second sex chromosome. It is a rare disease affecting 1:2500 live born girls [4].

Table 1: Characteristic clinical features of Turner syndrome

| Skin and adnexa | Mouth | Ears | Eyes | Neck | Skelatal system | Cardiovascular system | Blood | Metabolism | Nervoso system | Psychological |
|-----------------|-------|------|------|------|-----------------|-----------------------|-------|------------|---------------|--------------|
| plerygium; ↓ moles; vitiligo | palate with a pointed arch form (“O-shaped” palate); ↓ development of the jaw; mouth as a “cawl” | low implantation; ↓ development of the ear’s board; large ears; others malformations; neurosensonal defects | alteration in the position and shape of the eyelid (hypertelorism and epicanthal folds); strabismus; dyschromatopsia | short and squar | four short metacarpals; ↓ length of the fourth metacarpal bone (XR Archibald sign); cubitus valgus; medial condyle of the tibia agenesis (XR Kosowicz sign); delayed bone maturation (first three years of life, after ten years) | bicuspid aortic valve; aortic coarctation; aortic valve prolapse; hypertension; conduction defects | abnormalities of coagulation factors | abnormal lipid profile (cholesterol, triglycerides) and glucose | defects in visual-spatial and visual-perceptual skills; ↓ motor function (unable to walk before 15 months); ↓ non-verbal memory; ↓ attention | disorders in emotional |

The course of the disease is highly variable: it may spontaneously regress, be stable or progress to a severe form. Even if numerous treatment options are now available for AA (tab.2), no definitive therapy exists [15, 16].

In our case, the patient showed an excellent clinical response to cyclosporine A treatment, initially combined with intralesional corticosteroids.

In conclusion, the authors have presented this case study to record the possible association of AA with Turner syndrome, and therapeutic validity of cyclosporine in stimulating hair growth where other therapies had previously failed.

Table 2: Therapeutic options for alopecia areata

| Classical treatments | Promising treatments |
|----------------------|----------------------|
| Corticosteroids (topical, intralesional, systemic) | Azathiprine |
| PUVA therapy (topical or systemic & Methoxypsoralen + UVA) | Methotrexate |
| Topical immunotherapy (diphenyliyclopropenone/PUCL, squaric acid dibutyl ester/SADBE) | Tacrolimus |
| Antirheumatics | Pimecrolimus |
| Biological therapies | Biological therapies |
| Photodynamic therapy | Platelet rich plasma |
| Photodynamic therapy | UVA (340–410 nm) |

The Turner syndrome phenotype includes female gender, short stature, primary ovarian failure and some characteristic physical features (tab.1) [5]. Patients with Turner syndrome have an increased incidence of autoimmune disorders (AID), such as Hashimoto’s thyroiditis, Grave’s disease, celiac disease, inflammatory bowel disease, and diabetes mellitus [6-8].

Even if dermatologic autoimmune diseases (e.g. psoriasis, vitiligo, halo nevi) are well-known in Turner patients (9, 10), only a few cases of associated AA have been reported so far [11-13].

AA is a chronic inflammatory autoimmune disease, characterised by non-scarring hair loss on the scalp or any hair-bearing area of the body. Clinically it may represent in variable patterns, such as patchy, diffuse, reticulate, linear, or oipiates-type. Depending on the severity of hair loss, AA may also be classified as localised (few patches of hair loss), subtotal (diffuse alopecia of the scalp), total (complete loss of scalp hair) or universal (complete loss of body hair) [14].

References

1. Wolff H, Fischer TW, Blume-Peytavi U. The diagnosis and treatment of hair and scalp diseases. Dtsch Arztebl Int. 2016;113:377–386. PMid:27504707 PMCID:PMC4908932
2. Lazzarini R, Bilac Oliari C, Nasser Erthal AL. Late-onset alopecia areata: descriptive analysis of 30 cases. An Bras Dermatol. 2016;9:844-845. https://doi.org/10.1590/abd1806-4841.20165184 PMid:28098618 PMCID:PMC5193207
3. Alkilifah A, Alsantali A, Wang E, McElwee KJ, Shapiro J. Alopecia areata update: part I. Clinical picture, histopathology, and pathogenesis. J Am Acad Dermatol. 2010;62:177-188. https://doi.org/10.1016/j.jaad.2009.10.032 PMid:2151945
4. Nielsen J, Wohiert M. Chromosome abnormalities found among 34,910 newborn children: results from a 13-year incidence study in Arhus, Denmark. Hum Genet. 1991;87:81–83. https://doi.org/10.1007/BF01213097 PMid:2037286
5. Bondy CA. Care of girls and women with Turner syndrome: a guideline of the Turner Syndrome Study Group. J Clin Endocrinol Metab. 2007;92:10–25. https://doi.org/10.1210/jc.2006-1374 PMid:17947017
6. Lleo A, Moroni L, Caliari L, Invernizzi P. Autoimmunity and
Case Report

Turner’s syndrome. Autoimmun Rev 2012;11:A538–A543. https://doi.org/10.1016/j.autrev.2011.11.015 PMid:22154619

7. Larizza D, Calcaterra V, Martinetti M. Autoimmune stigmata in Turner Syndrome: when lacks an X chromosome. J Autoimmun 2009;33:25–30. https://doi.org/10.1016/j.jaut.2009.03.002 PMid:19349146

8. Jorgensen KT, Rostgaard K, Bache I, et al. Autoimmune diseases in women with Turner’s syndrome. Arthritis Rheum 2010;62:658–666. https://doi.org/10.1002/art.27270 PMid:20187158

9. Watabe H, Kawakami T, Kimura S, et al. Childhood psoriasis associated with Turner Syndrome. J Dermatol 2006;33:896–898. https://doi.org/10.1111/j.1346-8138.2006.00205.x PMid:17169099

10. Brazzelli V, Larizza D, Martinetti M, et al. Halo nevus, rather than vitiligo, is a typical dermatologic finding of Turner’s syndrome: clinical, genetic, and immunogenetic study in 72 patients. J Am Acad Dermatol 2004;51:354–358. https://doi.org/10.1016/j.jaad.2003.11.082 PMid:15337976

11. Tebbe B, Gollnick H, Muller R, et al. Alopecia areata and diffuse hypotrichosis associated with Ullrich-Turner Syndrome. Presentation of 4 patients. Hautarzt 1993;44:647–652. PMid:8225974